Bridged PROTAC is a novel protein complex degrader strategy that exploits the target
protein's binding partner to degrade undruggable proteins by inducing proximity to an E3 …

Transcription factors (TFs) and RNA-binding proteins (RBPs) have long been considered
undruggable, mainly because they lack ligand-binding sites and are equipped with flat and …

Transcription factors play central roles in numerous diseases yet are notoriously challenging
targets for drug development. In this issue of Cell Chemical Biology, Samarasinghe et …

Chemical knockdown of therapeutic targets using proteolysis targeting chimeras (PROTACs)
is a rapidly developing field in drug discovery, but PROTACs are bifunctional molecules that …

The development of effective and personalized treatment options for patients with rare
cancers like chordoma is hampered by numerous challenges. Biomarker-guided …

Targeted protein degradation (TPD) represented by proteolysis targeting chimeras
(PROTACs) marks a significant stride in drug discovery. A plethora of innovative …

Highlights•Traditional antibodies block ligand binding or drive Fc effector
functions.•Bifunctional antibodies function through an induced proximity …

The evolution of cancer treatment has provided increasingly targeted strategies both in the
upfront and relapsed disease settings. Small‐molecule inhibitors and immunotherapy have …

ATAC-seq has emerged as a rich epigenome profiling technique, and is commonly used to
identify Transcription Factors (TFs) underlying given phenomena. A number of methods can …

Despite the success of drug discovery over the past decades, many potential drug targets
still remain intractable for small molecule modulation. The development of proteolysis …